common equiti estim year-end
base pro forma data file ipo
way win best-in-class initi
initi coverag inc outperform pt base
view differenti approach nonalcohol steatohepat nash
sever hypertriglyceridemia shtg novel mechan action moa
promis earli clinic data low compar valuat
lead asset develop nash shtg two larg area unmet medic
need long-act glycopegyl fibroblast growth factor
analog engin use proprietari technolog prolong biolog activ
nativ believ potenti becom foundat nash
shtg therapi best-in-class among analog estim peak sale
nash shtg detail insid
target sever pathway lead nash progress provid
durabl lower triglycerid level base earli data endogen
metabol hormon regul carbohydr lipid metabol
inject glycopegyl analog prolong half-lif provid
potenti dose current
nash poc studi read
nash character inflamm fibrosi liver affect
us adult treatment current approv sad studi
demonstr improv key lipid paramet week follow singl
dose safety/toler believ potenti applic
patient assum launch estim peak sale
competitor analog nash pegbelfermin
appreci pegbelfermin strong data valid
moa nash albeit less-favor lipid profil frequent dose
data also show less-favor lipid profil
potenti toler concern view best-in-class
potenti superior efficaci safeti dose schedul
reduce-it studi demonstr triglycerid lower lead risk reduct
cv outcom demonstr signific durabl triglycerid
lower forese grow opportun patient refractori soc
shtg also provid risk diversif estim peak sale
believ under-valued compar base lower market cap
similar anticip develop timelin potenti superior asset sotp
analysi valu risk-adj opportun nash shtg
pt base dcf valuat initi outperform
year price histori
inc oper clinical-stag
biopharmaceut compani focus
nonalcohol steatohepat
liver metabol disord
san
headquart
analyst certif import disclosur see disclosur
posit data readout nash studi
shtg studi initi
shtg launch
nash launch
expedit path approv
path approv preclin asset
believ potenti becom foundat
nash shtg therapi best-in-class among
analog estim peak sale nash shtg
view rel under-valued
compar peer pt base dcf
unexpect clinic safeti signal
failur receiv approv
price target base dcf valuat methodolog assum wacc residu growth rate
due patent expir potenti competit entrant estim cash balanc includ
key downsid risk price target clinic develop risk regulatori risk current earli clinic
develop stage addit risk aris lower-than-expect peak sale estim due higher-than-anticip competit
failur gain support medic commun healthcar prescrib third-parti payor risk relat legal
challeng patent protect limit share float present potenti liquid risk ownership remain primarili concentr
among found investor could lead excess volatil risk downsid scenario balanc expect fund oper
anticip profit present potenti risk dilut financ
initi coverag inc outperform rate
price target base view differenti approach nonalcohol
steatohepat nash sever hypertriglyceridemia shtg novel mechan
action moa promis earli clinic data low compar valuat
etnb lead asset develop nash shtg two larg area unmet
medic need long-act glycopegyl inject fibroblast growth
factor analog engin use technolog prolong biolog activ
nativ believ potenti becom foundat
nash shtg therapi best-in-class among analog
endogen metabol hormon regul carbohydr lipid
metabol act multipl site reduc liver fat increas insulin sensit
suppress lipolysi believ analog potenti target
sever pathway lead nash progress includ steatosi inflamm
fibrosi preclin clinic studi demonstr benefici effect
broad rang metabol biomark well improv liver fat hepat injuri
fibrosi biomark suggest independ anti-fibrot effect studi
show robust durabl reduct serum triglycerid ldl-c
well increas hdl-c adiponectin current undergo
studi patient nash nafld high-risk nash evalu liver fat content
mri-pdff liver-rel metabol paramet
competitor also develop analog
favor view weekli everi two week dose compar
candid pegbelfermin daili weekli dose note potenti advantag
efficaci also favor view compar candid
base potenti superior dose regimen well better toler
studi qw dose result four withdraw due gi
side-effect four patient report tremor contrast reportedli
safe well-toler studi commonli observ trae
mild injection-sit reaction headach view favor compar
analog base receptor specif activ less bind
fgfr avoid block pathway enabl cholesterol
convers fatti acid explain biopharmaceut nash
trial show increas ldl-c note posit efficaci
valid approach treatment
view potenti foundat therapi nash base data show
insulin sensit ldl-c hdl-c triglycerid provid strong posit
monotherapi combin believ may use combin
nash therapi depend stage diseas progress thr-
agonist earlier-stag patient requir metabol therapi fxr
agonist later-stag patient requir fibrosi benefit shtg present
larg opportun risk diversif like faster path approv vs nash
share price perform gain sinc ipo nov
reflect grow market bullish price target base dcf valuat
assum probabl success nash ahead data
expect probabl success shtg develop view
direct compar base recent ipo similar stage develop
market capit believ rel under-valued
current market capit potenti superior therapi
price target base dcf valuat methodolog assum
wacc residu growth rate due patent expir
potenti competit entrant estim cash balanc
expect peak ww sale nash reach us
us market share initi us net annual price base
therapi repatha praluent assum probabl success
nash base current develop stage biomedtrack estim
less-establish nash market expect peak ww sale shtg
reach us us market share price equival
nash assum probabl success shtg base
current develop stage biomedtrack estim more-
establish shtg market assum pay teva royalti ww
revenu indic
key downsid risk price target clinic develop risk regulatori risk
current develop stage addit risk aris lower-
than-expect peak sale estim due higher-than-anticip competit
failur gain support medic commun healthcar prescrib third-
parti payor risk relat legal challeng patent protect
limit share float present potenti liquid risk ownership remain primarili
concentr among found investor could lead excess volatil risk
downsid scenario balanc expect fund oper anticip
profit present potenti risk dilut financ
upsid potenti price target aris better-than-expect clinic data
readout nash trial higher-than-estim futur
sale addit upsid potenti may aris favor licens deal develop
early-stag pipelin acquisit strateg competitor
anticip near-term catalyst includ shtg studi initi nash
studi data shtg studi data nash studi initi
shtg studi initi guid cash runway includ
potenti launch anticip nash regulatori submiss
follow studi data potenti launch
share price perform gain sinc nov ipo vs
 nbi reflect increas market awar
orbim advisor ra capit longitud capit pontifax
manag board represent venrock associ recent
file disclos ownership stake support posit outlook
note past perform view guarante futur result
inc clinical-stag biopharmaceut compani focus
develop commerci therapi treatment liver cardio-
metabol diseas viz nash shtg etnb lead product candid
glycopegyl analog current poc clinic trial nash
headquart san francisco ca oper herzliya israel
teva spin-out found orbim advisor led series-a financ syndic
longitud pontifax acquir right teva
restructur april rais gross proce
ipo share close nov anticip
cash runway cash burn rate
engin use proprietari glycopegyl technolog design
prolong biolog activ nativ preclin studi
demonstr signific improv hepat steatosi injuri fibrosi
single-ascend dose sad studi healthi volunt safe show
robust durabl reduct triglycerid improv key lipid paramet
two week dose-proport pharmacokinet pk profil follow singl
administr support potenti once-weekli everi two week dose sinc
inject administr asymptomat patient may pose adher risk
view potenti less-frequ dose critic competit advantag
poc trial initi juli screen on-going
patient nash nafld high-risk nash trial multicent random
double-blind placebo-control multiple-ascend dose-rang studi
patient receiv once-weekli everi two-weekli subcutan dose
placebo week trial design evalu safeti toler pk
properti primari endpoint imag biomark assess
key secondari endpoint includ percent-chang baselin liver fat reduct
measur mri-pdff week expect report top-line data
nash sever form nafld character inflamm fibrosi liver
progress cirrhosi liver failur hepatocellular carcinoma death
nash affect us adult risk factor includ excess calor overload
metabol dysregul cardio-metabol comorbid genet increas
likelihood develop nash commonli found peopl obes
diabet studi predict nash surpass hepat lead caus
liver transplant preval expect increas us
current approv product treatment nash
biopharmaceut industri activ engag address larg unmet need
shtg character elev level triglycerid associ
increas risk nafld nash cardiovascular cv diseas acut pancreat
estim us patient triglycerid level
estim patient dyslipidemia diabet
expect patient popul increas due on-going epidem obes
metabol syndrom diabet larg portion patient refractori
unabl achiev treatment goal soc therapi clinic studi
treat shtg patient unabl reduc triglycerid level
despit use approv therapi note mani therapi may decreas
triglycerid level gener broader metabol benefit
anticip initi shtg studi shtg top-line data expect
nonalcohol fatti liver diseas nafld nonalcohol steatohepat nash
caus liver diseas western countri nafld condit defin
excess fat accumul form triglycerid steatosi liver
hepatocyt histolog subgroup nafld patient liver cell injuri
inflamm addit excess fat steatohepat nafl spectrum
condit design nash dramat increas risk cirrhosi liver
failur nash wide consid liver express metabol
syndrom diseas relat diabet mellitu insulin resist central
hypertriglyceridemia hypertens exact progress diseas
understood especi multifactori caus accord two-hit
hypothesi first hit involv accumul tg hepatocyt caus
viciou cycl metabol dysfunct presenc hepat steatosi
establish progress steatohepat involv second hit oxid stress
exhibit progress nafld/nash
three underli activ use measur nash activ liver steatosi
inflamm hepatocyt balloon total na score repres sum score
steatosi lobular inflamm balloon rang accord
na prerequisit nash steatosi balloon discrimin factor
current approv endpoint nash fibrosi improv nash resolut
measur biopsi
exhibit score nash along clinic endpoint
patient typic asymptomat earli stage nafld diseas
suspect patient show elev level enzym alanine-transaminas alt
aspart transaminas ast non-invas techniqu mri
ultrasound ct use confirm steatosi transient elastographi fibroscan
detect fibrosi assess liver stiff gold standard way clinic
verifi nash liver biopsi key aim field develop non-invas test
nash nafld allow screen
exhibit diagnosi nash
standard care soc nash includ lifestyl chang better manag
relat metabol diseas diabet hyperlipidemia possibl bariatr
surgeri fda-approv pharmacolog treatment exist nash creat
larg opportun base unmet need
exhibit clinic endpoint nash
approxim individu us estim progress nash
nash-rel cirrhosi model approxim nash patient
us receiv treatment use younossi et al hepatolog templat
calcul proport nash patient fall categori nash without
fibrosi nash fibrosi nash compens cirrhosi nash
decompens cirrhosi nash portal hypertens
exhibit annual predict nafld case subcategori studi estim nash
patient fibrosi fb patient nash cirrhosi cr us alon
opportun nash
develop glycopegyl fibroblast growth-factor
analog nash fibrosi patient recent single-ascend dose sad trial
healthi volunt show signific improv key lipid paramet
day follow singl administr safeti toler recent initi
trial nash patient valid moa top-line data expect
investig nash compound target sever aspect multifactori diseas
fibrosi lipid inflamm insulin signal primari advantag
glycopegyl analog regul energi expenditur glucos homeostasi
insulin sensit therebi provid system metabol benefit rather directli
target lipid synthesi fxr ppar gnft thr
also gener on-target effect increas adiponectin
hormon releas adipos tissu suppress progress hepat fibrosi
exhibit categori moa nash
farnesoid receptor fxr transcript factor regul cholesterol alpha-
hydroxylas bile acid natur ligand fxr fxr play critic role bile
acid synthesi carbohydr lipid metabol regul insulin sensit
growth regener liver injuri bile acid circul liver
intestin back cycl call enterohepat circul fxr highli
express tissu particip bile acid metabol liver intestin
kidney high dietari cholesterol activ liver receptor shown
neg affect balanc storag oxid fatti acid
non-triglycerid metabolit diacylglycerol
lysophosphatidyl cholin drive lipotox injuri liver cell one critic fxr target
gene gut fibroblast growth secret growth factor
signal cell-surfac receptor tyrosin kinas fxr shown
involv liver cirrhosi activ hepat stellat cell hsc thought
mediat process liver fibrosi secret extracellular matrix protein
ultim lead scar liver tissu fxr activ also reduc hepat
express sterol regulatori element bind protein result reduc triglycerid
cholesterol content liver fxr also play critic role insulin sensit fxr
activ lower plasma glucos free fatti acid triglycerid total cholesterol
addit direct role fxr indirectli regul carbohydr lipid metabol
insulin sensit increas secret small intestin
exhibit moa fxr pathway nash
peroxisom proliferator-activ receptor ppar consist three identifi type
ppar ppar ppar ppar mainli influenc fatti acid metabol
activ lower lipid level ppar mostli involv regul
adipogenesi energi balanc lipid biosynthesi ppar/ particip fatti acid
oxid mostli skelet cardiac muscl also regul blood glucos
cholesterol level recogn ppar also modul inflammatori
fibrogenesi
tumorigenesi categori includ thiazolidendion tzd gnft elafibranor
cbay seladelpar recent discontinu clinic develop
regul cell divis associ
exhibit moa ppar pathway nash
anti-inflammatori compound aim reduc amount inflamm liver
liver great regen abil compensatori growth howev sustain
sever liver injuri lead scenario gener apoptot cell outpac
bodi abil effect remov surround tissu build-up
apoptot materi lead cell death increas inflamm disease-
driven excess apoptosi result develop scar tissu fibrosi
lead tissu destruct eventu reduc capac organ function
normal agn cenicriviroc cvc dual inhibitor protein call
play key role inflamm fibrosi
thyroxin regul ldl-cholesterol triglycerid
fatti liver insulin sensit hormon also regul bodi weight exert
physiolog effect bind specif nuclear receptor thr
wide distribut throughout bodi two isoform major
isoform liver kidney thyroid predominantli express
brain adipos tissu anterior pituitari gland specif target thr- rather
thr- critic avoid cardiac side effect thr- agon lower ldl-c
triglycerid clinic demonstr signific liver fat reduct mri-pdff
categori includ mdgl resmetiron vktx
exhibit moa thr- pathway nash
fibroblast growth factor fgf famili cell-sign protein involv
development process regul energi expenditur glucos homeostasi
insulin sensit fgf signal fgf receptor fgfr pathway primarili
includ ras/map-kinas pathway plc pathway
four distinct fgfr transmembran receptor extracellular
ligand bind domain intracellular tyrosin kinas activ fgf consid
autocrin paracrin local activ except endocrin fgf
exhibit system behavior endocrin fgf function local signal due
lower heparan sulfate-bind affin rather fgf requir -klotho
co-factor fgfr bind transmembran protein express adipos tissu
liver pancrea fgf specif target bloodstream
fgf c-terminu bind -klotho enabl n-terminu form expand complex
fgfr therebi initi intracellular signal cascad liver play critic role
multipl catabol anabol pathway includ bile acid lipid carbohydr
addit detoxif act endocrin signal bile acid metabol
liver function endocrin hepatokin glucos lipid metabol
notabl without bind system metabol effect suggest
potenti therapeut applic nafld nash
endocrin fgf regul bile acid glucos metabol
express small intestin control bile acid nuclear receptor fxr activ
preferenti activ liver repress therebi
downregul bile acid synthesi addit activ inhibit
gluconeogenesi increas hepat fatti acid oxid glycogen synthesi
suggest potenti applic diabet nash treatment howev
mitogen effect implic hepatocellular carcinoma seen rodent model
rais concern use chronic therapi aldafermin
modifi version current trial may lower activ
reduc risk maintain activ activ also block
pathway enabl cholesterol convers fatti acid explain previou
data nash diabet show signific increas ldl-c
exhibit moa pathway nash
degirolamo et al natur review drug discoveri kir et al spring harbor symposia quantit biolog
endocrin fgf predominantli express liver white adipos tissu
brain pancrea express regul fxr ppar rxr
ror nuclear receptor preferrenti bind affin less
affin fgfr bind unlik therebi provid
pleiotrop effect energi metabol glucos homeostasi insulin sensit
result weight loss inflamm reduct also increas adiponectin
hormon releas adipos tissu suppress progress hepat fibrosi
sinc short half-lif endogen preclud basic hormon supplement
engin variant improv pharmacokinet key interest potenti
therapeut applic first two develop candid lli
bmi pegbelfermin origin diabet discontinu
develop candid follow insignific efficaci shift develop
focu diabet nash base post-hoc analysi show efficaci
fibrosi lipid candid show improv
lipoprotein profil insulin sensit two studi diabet patient
current trial nash patient glycopegyl version
enabl prolong half-lif preclin studi show
improv glycem resist lipoprotein profil clinic studi healthi
volunt demonstr signific reduct serum triglycerid ldl-c
increas hdl-c adiponectin conduct studi
nash nafld patient high-risk nash current enrol
exhibit moa pathway nash
exhibit tissue-specif intracellular pathway metabol outcom
exhibit overview nash develop landscap
exhibit sever advantag featur compar moa nash
note data comparison absenc head-to-head studi
companyassetmoaphasenashstatusdataintercept obetichol acid oca fxr agonistnda filedfibrosi regener pivot result statist signific file fda approv statast signific stage fibrosi improv worsen nash oca mg vs placebo statist signific nash resolut worsen fibrosi oca mg vs placebo bridg fibrosi compens cirrhosistermin trial statist significancefail fibrosi improv worsen nash stage selonserib mg vs placebo signific genfit gnft elafibranor resolve-it trial on-going result expect end data posit fibrosi improv worsen nash mg elafibranor vs placebo vs former tobira cenicriviroc cvc immunomudul studi on-going preliminari result expect octob signific fibrosi improv worsen nash cvc mg vs placebo -select studi on-going preliminari result expect june statist signific reduct liver fat mri-pdff vs placebo vk -select biopsi studi initi statist signific reduct liver fat mri-pdff vs placebo balanc trial on-going top-line posit pk improv lipoprotein notabl safeti issuebristol-my squibb bm pegbelfermin studi statist signific reduct liver fat serum week pegbelfermin qw vs trial on-going top-line posit pk safeti data improv key lipid paramet biopharma initi statist signific reduct f-stage na week novn tropifexor full biopsi data expect signific reduct hepat fat alt vs placebo weeksenanta trial biopsy-proven nash initi statist signific reduct alt liver fat mri-pdff vs placebo weeksgilead studi ongoingstatist signific decreas densiti fat mg vs placebo vs seladelparppar pend evalu abnorm histolog find top-line result statist signific liver fat reduct seladelpar mg vs placebo statist signific liver enzym chang alt reduct seladelpar mg vs placebo gilead glmd aramcholfatty-acid bile-acid armor pivtoal studi signific fibrosi improv worsen nash aramchol mg vs placebo studi ongoingstatist signific decreas densiti fat mg vs placebo cnat emricasancaspas studi fail meet statist significancefail improv crn fibrosi stage emricasan mg mg vs placebo dual agonistn/an/ain-licens yuhan corp inc
view differenti among nash develop candid base
uniqu moa clinic valid efficaci advantag glycopegyl
technolog enabl longer half-lif protect proteolysi reduc renal
clearanc minim suscept aggreg solut optim potenc
glycopegyl process involv target mutat keep c-terminu
protein intact via substitut natur amino acid sequenc insert posit
near fap enzym cleavag site c-terminu critic -klotho
bind singl linear kda glycopeg moieti attach posit result
half-lif hour significantli longer pegbelfermin hour
exhibit long-act glycopegyl analog
believ posit pegbelfermin result de-risk ahead
top-line readout pegbelfermin qd qw demonstr
statist signific placebo-adjust absolut reduct liver fat content measur
mri-pdff reduct serum collagen deposit indic liver
stiff proxi fibrosi benefit pegbelfermin gener safe well-toler
exhibit moa clinic valid base pegbelfermin result
evalu seven anim studi nash diabet obes
includ studi mice non-human primat nhp preclin studi
observ consist benefici effect across rang relev endpoint
includ improv hepat steatosi injuri fibrosi diet-induc
nash studi mice improv glycem resist lipid handl reduct
bodi weight studi spontan diabet obes cynomolgu monkey
elev triglycerid believ result demonstr potenti
simultan address multipl driver nash pathogenesi histolog
endpoint nafld activ score na fibrosi score assess preclin
studi reflect endpoint expect assess clinic develop
exhibit summari nash preclin studi
result mous studi
conduct two pharmacolog studi mous model first studi
mg/kg everi day week follow detail assess liver
paramet evalu dose regimen effect dose
observ significantli reduc total na base histolog evalu improv
measur lipid metabol insulin sensit addit express hepat
gene involv inflamm fibrosi significantli reduc administr
second mous studi mice across five treatment group test
lower dose level mg/kg everi day longer
treatment durat week second studi demonstr signific
reduct diet-induc liver damag dose-depend manner addit
treatment demonstr signific mean reduct nash histolog
marker well reduct alanin amino transaminas alt key liver lipid
inflammatori fibrot marker dose-depend manner compar vehicl
treatment addit benefici therapeut effect liver treatment
demonstr signific improv glycem control weight loss
note support evid clinic efficaci given na measur
fibrosi histolog endpoint assess nash clinic studi
exhibit mous model show improv liver histolog
exhibit mous model show reduct alt
exhibit mous model show reduct liver lipid
result spontan diabet obes cynomolgu monkey studi
efficaci evalu spontan diabet obes cynomolgu
monkey across four treatment group multipl subcutan dose first
studi administ weekli dose mg/kg week
follow washout phase administr show signific
reduct triglycerid baselin dose includ robust reduct
observ highest dose mg/kg once-weekli statist signific mean reduct
observ total cholesterol glucos insulin glycat hemoglobin
alt along improv oral glucos test result
exhibit diabet monkey studi show signific reduct triglycerid alt
second multiple-dos studi spontan diabet obes cynomolgu monkey
across four treatment group administ week mg/kg
weekli mg/kg given everi two week observ rapid robust
reduct triglycerid statist signific mean reduct also
observ bodi weight glucos insulin along increas adiponectin
level improv oral glucos test result once-weekli everi two
week treatment group compar vehicl group note robust effect
bodi weight treatment period particularli unexpect
pd effect rel similar across three dose group suggest
everi two week could viabl clinic dose strategi
exhibit diabet monkey studi show signific reduct bodi weight
singl ascend dose sad trial volunt
pursu indic nash fibrosi random
double-blind placebo-control first-in-human sad clinic trial healthi
volunt subject receiv subject receiv placebo
treatment reportedli well-toler treatment-rel advers
event trae report mild seriou advers event sae report
singl dose mg higher observ signific improv key
lipid paramet measur day day follow dose day mean
chang vs baselin includ reduct triglycerid ldl-c
increas hdl-c despit baselin valu within normal rang
mean chang statist signific vs placebo start
day demonstr rapid sustain durabl improv lipid
paramet two week singl dose administr believ
durat effect support possibl extend dose interv
observ preclin studi
sad trial design evalu safeti toler pk
healthi volunt trial enrol total healthi volunt one seven
cohort random receiv either singl dose placebo forty-thre
subject receiv dose mg mg mg mg mg mg
mg pk profil gener linear dose-proport
slightli dose-proport rang approxim hour
observ median time maximum serum concentr rang hour
exhibit pk profil exhibit gener linear dose-proport
healthi volunt baselin characterist mean sd age year
laboratori paramet normal rang mean valu
tg mg/dl ldl-c mg/dl hdl-c mg/dl healthi volunt studi
popul singl dose administr dose mg higher
result robust durabl pd effect observ across key lipid paramet includ
triglycerid ldl-c hdl-c two week chang key lipid paramet start
day maxim effect routin observ day day effect key
lipid paramet gener dose-depend singl dose mg
higher demonstr signific improv baselin measur day
day follow administr efficaci appear plateau mg
minim addit effect observ mg dose
exhibit summari effect lipid paramet sad studi
exhibit singl dose significantli reduc triglycerid day
exhibit singl dose significantli reduc ldl-c day
exhibit singl dose significantli increas hdl-c day
exhibit singl dose show increas adiponectin day
well-toler across dose rang trial death
discontinu due commonli observ trae
pool group inject site reaction headach report mild
inject site reaction frequent mg cohort like due larger
inject volum administ one time clinic meaning trend observ
gastrointestin gi event laboratori vital sign includ blood pressur heart
rate chang tremor report subject
test posit anti-drug antibodi ada howev titer low
appear affect pk safeti profil view overal clinic safeti
toler profil clean highli encourag
believ safeti toler result especi favor compar
direct competitor candid studi
mg qw dose result four withdraw due gi side-effect four
patient report tremor also note earn press releas
disclos complet nonclin toxicolog studi requir support
trial expect later origin expect expect similar
develop timelin anticip initi
exhibit studi trae report treatment-rel withdraw
proof-of-concept poc trial nash/nafld
total clinic preclin data support advanc
studi patient nash nafld high-risk nash establish
poc potenti treatment nash base pk/pd model
drug exposur analysi identifi dose rang mg mg
weekli qw everi week target dose rang evalu
clinic trial patient nash nafld high risk nash ultim
pursu indic nash fibrosi target patient
patient sweet spot believ total previou clinic preclin
data well competitor data support hypothesi applic
nash treatment view data magnitud signific durabl
metabol chang safeti toler compar better
competitor result although note head-to-head studi done
poc clinic trial initi juli patient current
enrol trial design multicent random double-blind placebo-control
multiple-ascend dose-rang trial patient nash nafld high-risk
nash inclus criteria requir least one biopsy-confirm nash
fibrosi stage without cirrhosi central obes diabet
and/or central obes either increas alt and/or fibroscan vcte score kpa
patient random receiv qw subcutan dose
placebo week trial assess safeti toler pk properti
primari endpoint chang liver fat measur mri-pdff
key biomark assess secondari endpoint anticip data provid poc
nash contribut inform dose select larger long-term
paired-biopsi trial previous met fda june fda agre
overal trial design includ studi popul dose select treatment durat
exhibit poc trial nash/nafld design
activ treatment group mg qw mg
expect two dose-escal decis point studi due
design multiple-ascend dose-rang studi first decis point move
mg qw dose cohort mg qw mg dose cohort
second decis point move two dose cohort final three dose
cohort expect dose-escal decis day assess relev
cohort trial design detect differ mri-pdff vari
dose level vs pool placebo group week expect report top-line data
anticip initi trial
differenti nash
bmi pegbelfermin pegyl form current undergo
studi nash pegberfermin report half-lif hour includ
mutat non-n amino acid substitut studi pegbelfermin show
signific reduct absolut liver fat measur mri-pdff signific
decreas concentr biomark fibrosi signific chang
lipid marker studi outcom better dose daili vs weekli inject
pegbelfermin gener safe well-toler higher frequenc gi
report treat patient also treat patient test posit
anti-drug antibodi view favor differenti vs
pegbelfermin primarili base potenti superior dose schedul hdl-c increas
overal cleaner safeti toler profil
exhibit vs pegbelfermin differenti lipid paramet
note data comparison absenc head-to-head studi pegbelfermin data base intern estim
akro long-act fusion protein extend half-lif
day complet studi diabet patient show decreas
triglycerid increas hdl-c well improv insulin sensit
howev modest chang ldl-c dose approxim
advanc develop previous note highest dose test
singl multiple-ascend dose studi well-toler includ
gi disord tremor current undergo balanc studi
nash weekli dose believ offer potenti better efficaci
ldl-c reduct like superior dose schedul far cleaner safeti toler
profil view closest competitor base similar moa
anticip develop timelin market capit
aldafermin engin variant develop
once-daili inject treatment nash preliminari result clinic trial
demonstr statist signific reduct liver fat liver transaminas
biomark fibrosi translat improv liver histolog fibrosi
week howev observ signific increas ldl-c aldafermin current
undergo alpin dose-rang studi patient biopsy-confirm
nash stage liver fibrosi view favor compar
analog base receptor specif activ
less bind fgfr avoid block pathway enabl
cholesterol convers fatti acid explain ldl-c increas trial
also believ offer potenti better efficaci dose schedul
exhibit nash model us sale estim
model sale nash model nash patient
us receiv treatment use younossi et al hepatolog templat
calcul proport nash patient fall categori nash without
fibrosi nash fibrosi nash compens
cirrhosi nash decompens cirrhosi nash portal
hypertens assum label indic stage appli
diagnosi rate improv per year assum market
penetr rate increas peak due assum patent expir
potenti competit entrant assum launch initi
annual us price base therapi praluent repatha assumpt
drive estim peak us sale nash assum
popul incid rate eu japan vari price assum
partner eu japan receiv royalti estim ww
peak sale appli probabl success
nash base current stage develop trial biomedtrack
estim potenti path approv less-establish nash market drive
estim peak ww risk-adjust sale
us nash popul nash popul growth treat nash popul nash nash without fibrosi fibrosi compens cirrhosi decompens cirrhosi ratesnash without fibrosi fibrosi compens cirrhosi nash without fibrosi nash fibrosi nash compens cirrhosi without fibrosi fibrosi nash fibrosi price price nash fibrosi us sale outperform
opportun shtg
plan develop treatment sever hypertriglyceridemia shtg
hypertriglyceridemia htg character elev fast plasma triglycerid level
mg/dl shtg typic defin triglycerid level mg/dl shtg
associ increas risk nafld nash cardiovascular cv diseas
estim acut pancreat incid recent publish result
amrn reduce-it cv-outcom studi vascepa icosap ethyl
fatti acid demonstr linkag reduct triglycerid
favor cv clinic outcom primari endpoint includ risk-reduct cv death
non-fatal myocardi infarct non-fatal stroke coronari revascular unstabl
angina believ result highlight larg unmet need valid approach
cv outcom improv triglycerid reduct therapi
exhibit reduce-it result demonstr improv cv outcom year
bhatt et al new england journal medicin
accord epidemiolog studi us patient triglycerid tg
level mg/dl shtg patient popul expect increas due
prevail epidem obes metabol syndrom diabet believ
address market expand base increas awar physician
import treat elev tg level especi light increas
evid cv-outcom risk-reduct similar focu manag ldl-c level
becom bolster competitor commerci effort promot tg reduct
treatment amrn promot vascepa
exhibit approxim shtg patient refractori approv treatment
note cite refractori rate base vascepa epanova clinic trial data
current soc shtg includ dietari restrict lifestyl chang lipid-low
treatment fibrat fish oil niacin statin may indic htg
indic use shtg note treat shtg patient
refractori soc unabl reduc triglycerid level mg/dl
refractori patient substanti unmet medic need given current
avail therapi indic refractori shtg believ
potenti address unmet patient popul base robust durabl triglycerid
level reduct observ clinic trial
exhibit limit approv treatment shtg present market opportun
limit approv treatment shtg preclud use wide varieti patient
fibrat show triglycerid reduct week treatment
also advers shown ldl-c increas risk drug-drug
interact increas transaminas well myopathi among toler
issu fish oil shown even less efficaci triglycerid reduct
baselin fish oil reduc triglycerid higher percentag
also show ldl-c increas note patient burden fish oil requir high
daili dose despit limit avail therapi achiev commerci
success view proxi market potenti shtg
exhibit hypertriglyceridemia landscap consensu sale forecast product
note sever agent current develop shtg includ fish oil product
fibrat among therapi target rare genetically-defin subset shtg
apoc-iii inhibitor apart shtg dyslipidemia also remain
activ area pharmaceut develop view differenti
approach shtg therapi base pleiotrop metabol benefit potenti
broader commerci beyond treat rare genet subset
previous demonstr signific reduct triglycerid level
preclin nhp studi clinic studi diabet obes cynomolgu monkey
elev triglycerid level show signific effect triglycerid
maxim reduct mg/kg dose monkey baselin triglycerid level
three treat monkey mg/kg weekli dose
show tg reduct study-end studi healthi volunt
patient baselin triglycerid level within normal rang mean baselin mg/dl
treat singl dose demonstr reduct triglycerid
baselin day note current approv shtg therapi
decreas tg level gener broader metabol benefit anticip
subsequ clinic trial demonstr signific decreas
tg ldl-c level improv metabol paramet provid substanti
reduct triglycerid obes diabet patient expect initi
studi shtg patient evalu reduct fast plasma triglycerid
level rel baselin top-line data expect base studi success
anticip initi pivot trial shtg patient year-end
exhibit plan path develop shtg
view shtg opportun strateg advantag potenti synergist
nash opportun provid diversif like quicker path
regulatori approv revenu gener note regulatori preced us
approv therapi treat shtg base studi show reduct triglycerid
week fda surrog endpoint tabl drug approv list reduct
triglycerid endpoint full approv therapi shtg clinical-outcom
studi requir amrn vascepa approv shtg post-market
commit triglycerid reduct indic mani registr shtg trial
product candid consist singl studi patient per treatment group
note overlap nash market nash patient htg
htg patient like nash base fda guidanc regulatori path follow
compani success develop shtg therapi believ
combin smaller clinic trial shorter develop timelin result
rel quicker path market shtg compar nash
exhibit shtg model us sale estim
model sale shtg model shtg patient
tg mg/dl base incid rate averag found
christian et al fan et al respect assum refractori rate
base vascepa epanova clinic result feedback kol due-dilig
convers assum market penetr rate increas
peak due assum patent expir potenti competit entrant
assum launch price equival nash assumpt drive
estim peak us sale shtg assum similar
popul incid rate eu japan vari price assum
partner eu japan receiv royalti estim ww peak sale
appli probabl success shtg
base current stage develop biomedtrack estim potenti path
approv more-establish shtg market drive estim peak ww risk-adjust
sale
us shtg popul age patient patient tg patient refractori patient refractori patient treatment- market penetr price therapi net price sale us outperform
exhibit total revenu forecast nash shtg
exhibit estim unadjust risk-adjust sale nash shtg
risk-unadjust revenu nash ww shtgu ww risk-unadj product revenu probabl success probabl success nash ww shtgu ww risk-adj product unadjust sale nash risk-adjust sale nash shtg inc
retain exclus world-wide right protect famili
issu patent claim direct composit matter method use
compani reli licens teva sublicens ratiopharm gmbh
teva affili patent know-how relat glycopegyl technolog
use develop manufactur commerci first
patent project expir us final composition-
of-matt patent project expir us case without patent term
extens biolog drug market approv also expect
provid year market exclus us approv date biolog
licens applic bla anticip first bla approv shtg
assum ip protect
manag board director
exhibit manag board director
rohan palekar serv chief execut offic member board
director sinc june prior join mr palekar serv presid
chief execut offic avanir pharmaceut inc specialti pharmaceut
compani decemb juli led compani follow
acquisit otsuka pharmaceut co ltd mr palekar also serv
execut vice presid chief oper offic avanir senior vice
presid chief commerci offic avanir march march prior
avanir serv chief commerci offic mediv inc biopharmaceut
compani respons commerci activ
chemistri manufactur control medic affair public relat function prior
mediv mr palekar spent year johnson johnson diversifi
healthcar compani variou senior commerci strateg manag role mr
palekar earn tuck school busi dartmouth colleg
 com account univers mumbai law
univers mumbai
positionoffic directorceo directorrohan palekarcoo cboram waisbourdcforyan martinscmohank mansbach cto head qualityquoc le-nguyendirectorderek dirocco ph directorgregori grunberg directormichael hayden ch ph directortom karivdirectoranat naschitz outperform
ram waisbourd serv chief oper offic chief busi offic sinc
may prior join mr waisbourd serv vice presid strategi
transform global research develop teva pharmaceut industri
ltd pharmaceut compani novemb april
respons teva research develop strategi novel pipelin fund
transact digit initi also serv vice presid transform
initi oper global research develop teva septemb
octob senior director chief research develop offic
august august previous mr waisbourd serv vice presid
busi develop ltd biotechnolog compani
vice presid biomed invest invest fund mr waisbourd earn
 tel-aviv univers sc econom wharton school
univers pennsylvania
ryan martin serv chief offic sinc juli previous
serv consult sinc april prior join mr martin cfo
revolut medicin inc march octob respons
aspect financ function includ financi account capit plan
audit tax investor relat vice presid
head corpor strategi investor relat ultragenyx pharmaceut inc
septemb march respons strateg plan
capit rais investor relat assist busi develop prior ultragenyx
mr martin spent nearli year biotechnolog analyst jefferi lazard
barclays/lehman brother hold oper role chiron corpor
mr martin earn sc life scienc st xavier colleg
degre biolog virginia haa school busi
hank mansbach serv chief medic offic sinc decemb prior
join dr mansbach ultragenyx pharmaceut inc biotechnolog
compani serv head global clinic develop metabol
neurolog diseas june decemb vice presid global clinic
develop ultra program march june vice presid
medic affair may march time ultragenyx dr
mansbach respons lead clinic develop program metabol
disord build lead medic affair team ultragenyx dr
mansbach serv vice presid medic affair mediv
biopharmaceut compani august april play key role
develop commerci enzalutamid treatment advanc
prostat cancer earlier career dr mansbach serv senior vice presid
global drug develop valeant pharmaceut cortex
pharmaceut inc pharmaceut compani began industri career glaxo
wellcom clinic practic research neurolog earn duke
univers philosophi yale univers
quoc le-nguyen serv chief technic oper offic head qualiti
sinc march prior join mr le-nguyen senior vice presid
global head technic oper qualiti aduro biotech inc biotechnolog
compani septemb juli respons clinic suppli
includ analyt process develop manufactur suppli chain qualiti
cell therapi small molecul antibodi platform prior aduro mr le-nguyen
vice presid manufactur oper bayer ag septemb
septemb respons betaferon/betaseron franchis prior
bayer mr le-nguyen work biolog manufactur ag
chiron corpor biomarin pharmaceut inc mr le-nguyen earn
biochemistri univers california davi
board director
derek dirocco ph serv member board director sinc april
dr dirocco princip ra capit manag llc invest
advisori firm invest healthcar life scienc compani sinc decemb
previous analyst june decemb associ
juli june dr dirocco earn ph pharmacolog
univers washington biolog colleg holi cross
gregori grunberg serv member board director sinc april
dr grunberg manag director longitud capit manag co
llc ventur capit firm sinc februari prior join longitud dr grunberg
princip rho ventur ventur capit firm work may
januari dr grunberg maintain limit clinic practic intern medicin
affili univers california san francisco kaiser permanent dr
grunberg serv board pharmaceut inc pharmaceut
compani sinc april welbehealth llc privat healthcar servic compani
sinc april serv board observ sydnexi inc privat
biotechnolog compani sinc septemb previous serv board
california cryobank acquir gi partner august august led
longitud invest practic fusion acquir allscript healthcar solut
inc rho ventur serv board aquesi inc acquir
allergan plc june decemb board observ
sarcod bioscienc inc acquir shire plc june februari
pht corpor acquir eresearchtechnolog inc novemb
novemb dr grunberg earn duke univers
 econom english amherst colleg
michael hayden ch ph serv member board director
sinc april dr hayden current killam professor univers british
columbia director translat laboratori genet medicin
nation univers singapor dr hayden presid global
research develop chief scientif offic teva may
decemb serv advisor teva decemb august
time approxim new product approv major market
mani diseas migrain led develop first deuter
drug approv fda second drug ever approv huntington
diseas also founder senior scientist centr molecular
medicin univers british columbia dr hayden serv
pharmaceut inc sinc septemb xenon pharmaceut inc sinc
novemb dr hayden receiv ch medicin ph genet
diploma child health univers cape receiv american board
certif intern medicin clinic genet harvard medic school
frcpc intern medicin univers british columbia
board aurinia
tomer kariv serv member board director sinc may mr kariv
serv co-found manag partner pontifax group ventur capit
firm sinc decemb serv board inc sinc
decemb logicbio therapeut inc sinc june previous serv
board inc januari june medic compress
system ltd august april macrocur ltd march januari
inc septemb august check-cap ltd
march june mr kariv earn econom harvard
univers harvard law school
naschitz serv member board director sinc januari
play key role creat ltd spin-out pharmaceut compani ms
naschitz serv manag director orbim global healthcar invest
firm sinc januari ms naschitz year healthcar experi
previous ms naschitz creat invest advis healthcar compani across
stage substanc associ partner mckinsey london
manag strategi compani format spinout merger
acquisit project senior manag world lead pharmaceut
biotechnolog compani subsequ ms naschitz princip apax
partner invest healthcar compani current serv
board biotech digit health compani serv board medigu ltd
medic devic compani march june ms naschitz earn
insead tel aviv univers
compar closest competitor nash base moa develop
stage clinic result valuat use current market cap enterpris valu ev
consid appropri compar base similar moa
current develop stage similar anticip timelin believ
potenti superior therapi nash compar base
clinic efficaci safeti data like dose schedul view rel
under-valued market cap vs market cap also note
market cap reflect potenti
reach similar later-stag develop interest compar
asset also develop two indic viz nash hypercholesterolemia
exhibit compar peer yield valuat insight
companyassetmoastatusdatamarket cap enterpris valu icptobetichol acid oca fxr statast signific stage fibrosi improv worsen nash oca mg vs placebo statist signific nash resolut worsen fibrosi oca mg vs placebo -select statist signific reduct liver fat mri-pdff vs placebo -select statist signific reduct liver fat mri-pdff vs placebo posit pk improv lipoprotein notabl safeti issu recent began dose balanc posit pk safeti data improv key lipid paramet recent began dose statist signific reduct f-stage na week posit fibrosi improv worsen nash mg elafibranor vs placebo vs inc
sotp analysi valu nash shtg
estim npv indic appli wacc termin growth rate
consist dcf valuat appli respect probabl success
nash shtg arriv probability-adjust value-per-share
estim cash balanc equat approxim
exhibit sotp analysi valu nash shtg
price target base dcf valuat methodolog assum
wacc residu growth rate due patent expir
potenti competit entrant estim cash balanc
expect peak ww sale nash reach us
us market share initi us net annual price base
therapi repatha praluent assum probabl success
nash base current develop stage biomedtrack estim
less-establish nash market expect peak ww sale shtg
reach us us market share price equival
nash assum probabl success shtg base
current develop stage biomedtrack estim more-
establish shtg market assum pay teva royalti ww
revenu indic
exhibit dcf valuat methodolog drive pt
drug/indicationexpect launchpeak sale estim mm npv mm estimate probabl success valu sharep-adj npv mm p-adj valu equiti share outstand use valuat valu growth valu valu per sharetermin valu growth rate outperform
exhibit incom statement forecast
inc except per share data fy probability-adj product revenues- nash- probabl sales- shtg- probabl sales- collabor revenu milestones- total revenues- total cogs- goods- royalti teva- gross profit- oper expensesresearch develop adjust research develop share-bas compens total share-bas gener administr adjust sell gener administr share-bas compens total share-bas share-bas compens exclud non- op other- total oper expens oper incom expens interest incom expens net- realiz gain loss investments- pre-tax incom incom tax expens tax basic share outstand share outstand ep ep oppenheim co estim compani data inc
exhibit statement forecast
inc fy incom stock-bas compens defer tax revalu convers prefer share realiz loss gain investment- other- chang oper asset liabilitiesaccount receivable- inventories- prepaid expens current account accru expens current leas amortization- flow sale purchas investments- proce matur investments- purchas properti flow proce issuanc common stock net- proce issuanc convert prefer share proce issuanc convert note public offer financ costs- repay convert note payable- valu share withheld relat employe tax witholding- proceed exercis option warrants- flow effect fx- net increas decreas equival beginning- equival sourc oppenheim co compani report outperform
exhibit balanc sheet forecast
inc fy asset cash market secur avail sale- prepaid clinic trial expenses- prepaid expens current account receivable- inventories- restrict total current properti equip oper leases- defer public offer financ expenses- defer tax non-curr assets- total liabilitiescurr liabil account accru leas liabil current- accru interest- convert prefer share liabil current debt convers featur liability- total current defer rent- long-term debt- leas liabil long-term- long-term liabilities- total stockhold equityconvert prefer common addit paid-in accumul accumul comprehens income- total stockhold total liabil stockhold sourc oppenheim co compani report inc
inc discount analysi except per-shar data revenu growth chang work work capit valu growth valu probabl success probabl success oppenheim co equiti valu per sharetermin valu growth rateequ valu per shareprob success nashprob success shtg outperform
stock price compani mention report
